Navigate clinical trials

What is Trial Navigator?

Trial Navigator is a specialized agent in Owkin K that helps pharmaceutical and clinical teams explore the clinical trial landscape using plain-language questions. You ask the way you'd ask a colleague; it interprets the intent, filters a large clinical-trials dataset, and returns the right output: a visual timeline, a data table, a statistical projection, or a direct answer.

Use it to:

• Map competitive landscapes across an indication, mechanism of action, or drug class
• Track competitor pipelines and development timelines
• Answer quantitative questions about the trial landscape (counts, averages, distributions)
• Compare trials against a reference trial (e.g. "PFS better than trial X")
• Deep-dive a single trial's design assumptions and projected readout times

How it works

You don't need to know the internals to use Trial Navigator, but a quick mental model helps you write better queries. Behind the scenes it:

1

Plans

Breaks a complex question into sub-questions and, when needed, runs them in sequence, so "find trials better than X" first finds X, then compares the rest of the landscape against it.

2

Translates

Turns your words into structured filters: indication, phase, sponsor, dates, mechanism of action, enrollment thresholds, and more.

3

Reconciles terminology

Maps your wording to the dataset's standard names via a built-in thesaurus, so "immunotherapy", "IO", and "PD-1 inhibitor" resolve to the right underlying terms.

4

Answers

Returns a Gantt chart and table, a statistical projection, and/or a written summary, depending on what you asked for.

You can be conversational and use common abbreviations, the tool is designed to resolve them. The more specific you are, the sharper the result.

See it in action

Writing effective queries

• Name the therapeutic area / indication (e.g. NSCLC, TNBC, glioblastoma).
• Name the mechanism of action or drug class when relevant (PD-1/PD-L1, EGFR TKI, ADC, VEGFR, CLDN18.2).
• Name sponsors, drugs, or NCT IDs when you have them.
• Add a phase to narrow the development stage (Phase I, II, III, I/II…).
• Add a timeframe ("started after 2020", "between 2018 and 2023").
• Add thresholds ("enrollment greater than 500", "accrual target of exactly 500").
• Use exclusions freely ("excluding Phase I", "excluding breast and prostate cancer").
• Ask for top / latest / longest when you want a ranked shortlist ("the 5 most recent…", "longest-running…").

What you can ask

Competitive landscape / list trials

Returns an interactive Gantt chart, a detailed results table, and summary statistics.

What are the clinical trials for immunotherapy in lung cancer?
Show me immunotherapy trials for breast cancer started in 2020 or later.
Find PD-1 or PD-L1 antagonist trials for colorectal cancer
Find EGFR tyrosine kinase inhibitor trials for lung cancer in Europe
Show me all Phase 1/2 studies for CLDN18.2 ADCs
Show me gene therapy trials for glioblastoma started after 2018

Complex multi-filter queries

The tool handles several constraints at once, combining indication, phase, geography, dates, mechanism, and thresholds.

Find Phase II and III immuno-oncology trials for breast or lung cancer in
Europe or North America, started between 2018-2023, with enrollment at least
500 patients
Show me VEGFR tyrosine kinase inhibitor trials for prostate or colorectal
cancer in Asia, started between 2010-2020, excluding Phase I trials
Show me all Phase 3 Merck & Co. studies in NSCLC evaluating ADCs
Chart all Roche P3 studies for atezolizumab in TNBC that have published data

Ranked / "top N" / "latest N" / "longest-running"

Ask for a ranked shortlist instead of the full set.

Show me the 5 most recent AstraZeneca-sponsored clinical trials
What are the longest-running clinical trials for melanoma?
Show me recent small trials with high objective response rate

Aggregate & quantitative questions

For counts, averages, percentages, and "what's covered" questions, the tool answers directly in text, with supporting figures where useful.

How many clinical trials are there for lung cancer started between 2015 and 2024?
How many trials are sponsored by Roche that started in 2020?
What is the average accrual target for Phase III trials?
What percentage of ADC trials are Phase III?
What is the most common indication for HER2-targeting ADC clinical trials?

Comparative queries (against a reference trial)

The tool can find a reference trial first, then compare the rest of the landscape against it.

Find trials with progression-free survival greater than trial NCT00490139
Find trials with overall survival greater than trial NCT00490139 for breast cancer

Single-trial statistical analysis

Deep-dive the statistical assumptions behind a specific trial's design and projected readout times. Returns a projection plot, predicted median OS/PFS, predicted enrollment duration, and the reference trials used for the prediction.

Show me the details for trial NCT00490139
Perform a statistical analysis for trial NCT00338247
What are the underlying assumptions for read out times of trial NCT00490139?

Understanding the outputs

Gantt chart (timeline)

• X-axis: time (years)
• Y-axis: individual trials, grouped by phase and sorted by start date
• Colour: trial phase; bars show duration with mechanism-of-action abbreviations
• Includes both industry-sponsored and publicly/academically sponsored trials.

Results table

A sortable, filterable list of every matching trial: NCT ID (linked to ClinicalTrials.gov), sponsor, phase, indication, drug/mechanism, and key results.

Summary statistics

An automatically computed answer summary, for example total trial count, phase distribution, and top indications represented.

Statistical projection plot

For single-trial analysis: an enrollment curve and survival projections, with the reference trials (by NCT ID) used to generate the predictions.

PowerPoint export

Trial Navigator can export a competitive-landscape view into a PowerPoint slide.

PowerPoint export is a newer, deployment-gated capability, availability depends on your K environment.

Searchable data fields

Trial Navigator is built on a comprehensive oncology clinical-trials dataset sourced from ClinicalTrials.gov. You can filter and search across the following dimensions.

Identification

Field	Description
NCT ID	ClinicalTrials.gov identifier
Brief Title	Short trial title
Official Title	Full formal trial title
Commercial Name	Sponsor's commercial trial name

Status & timeline

Field	Description
Overall Status	Recruiting, Active Not Recruiting, Completed, Terminated, etc.
Trial Start Date	Date the trial began
Primary Completion Date	Date of primary outcome measurement
Completion Date	Full study completion date
Trial Duration	Duration in days

Design

Field	Description
Study Type	Interventional, Observational
Trial Phase	I, II, III, IV, I/II, II/III, III/IV
Randomization	Whether the trial is randomized
Number of Arms	Count of treatment arms
Group Types	Experimental, Active Comparator, Placebo Comparator, etc.

Sponsors

Field	Description
Private / Industry Sponsors	Pharmaceutical and biotech companies (Pfizer, Roche, AstraZeneca, etc.)
Public / Academic Sponsors	Universities, hospitals, research centers, government agencies
Industry Sponsored	Boolean flag for industry involvement

Enrollment & accrual

Field	Description
Enrollment	Number of participants
Accrual Target	Target number of subjects
Accrual Actual	Actual enrolled subjects
Enrollment Duration	Time to complete enrollment (days)

Geography

Field	Description
Trial Countries	Countries where the trial is conducted
Trial Regions	Regions (North America, Western Europe, Asia, etc.)
Number of Sites	Count of trial sites

Eligibility criteria

Field	Description
Gender	Both, Female Only, Male Only
Age Range	Minimum and maximum age for eligibility
ECOG Status	Performance status requirements (0-4 scale)
Disease Stages	Localized, locally advanced, advanced, metastatic, resectable, unresectable
Disease Paths	Persistent, recurrent, refractory, relapsed, resistant
Lines of Therapy	Prior treatment requirements

Indications (cancer types)

Trial Navigator covers a comprehensive oncology landscape, including:

Solid tumors:

• Breast, Lung (NSCLC, SCLC), Colorectal, Pancreas
• Melanoma, Renal, Bladder, Prostate
• Head/Neck, Esophageal, Gastric, Liver
• Ovarian, Endometrial, Cervical
• CNS tumors (Glioblastoma, Astrocytoma, Meningioma, etc.)
• And many more

Hematological malignancies:

• Leukemia (ALL, AML, CML, CLL)
• Lymphoma (Hodgkin's, Non-Hodgkin's)
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myeloproliferative Neoplasms

Treatment & intervention

Field	Description
Drug Names	Investigational drug names
Drug Type	ADC, Antibody Bispecific, Antibody Multispecific, Gene Therapy, Small Molecule
Mechanisms of Action	JAK inhibitor, CDK inhibitor, PD-1/PD-L1 inhibitor, etc.
Targets (HGNC)	Gene symbols (KRAS, TP53, BRCA1, EGFR, ERBB2, etc.)
Biomarkers	Biomarkers used in trial selection
Combination Therapy	Whether the trial tests a drug combination

Endpoints

Field	Description
Primary Endpoints	OS, PFS, DUAL, or other
Has OS	Overall Survival as endpoint
Has PFS	Progression-Free Survival as endpoint
Has EFS/DFS/RFS	Event-free, Disease-free, Recurrence-free Survival

Outcomes (actual & predicted)

Field	Description
Objective Response Rate	ORR from trial results
Disease Control Rate	DCR from trial results
Median OS (months)	Actual median overall survival
Median PFS (months)	Actual median progression-free survival
Predicted Median OS	AI-predicted median OS
Predicted Median PFS	AI-predicted median PFS
Predicted Enrollment Duration	AI-predicted time to complete enrollment

Tips & good-to-knows

• Be conversational, but specific. Abbreviations and synonyms are resolved by the thesaurus; specificity narrows results.
• Smart name resolution. The tool understands common synonyms and variations, for example "Keytruda" maps to pembrolizumab, "Herceptin" to trastuzumab, gene-name variants (ERBB2 / HER2 / neu), and sponsor name variations (Merck & Co., MSD, Merck Sharp & Dohme).
• Large landscapes are shown, not silently truncated. The chart focuses on the most relevant trials for readability while the underlying query covers the full matching set. If a very large landscape is capped for display, the tool tells you.
• Statistical projections are model-based estimates, derived from historically comparable reference trials. Treat them as directional, not definitive, and note they are available only for Phase II and III trials with sufficient historical data.
• Coverage is oncology-focused. Non-oncology questions may return limited or no results.
• Data reflects ClinicalTrials.gov, so completeness depends on what sponsors have registered and published. For real-time status, verify directly on ClinicalTrials.gov.